IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Condense Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Mime-Version:
1.0
Sender:
Information and Referral and Internet Sightings <[log in to unmask]>
Subject:
Quebec includes Abilify in public drug plans
From:
Sylvia Caras <[log in to unmask]>
Date:
Wed, 27 Oct 2010 09:31:26 -0700
Message-ID:
<[log in to unmask]>
Content-Type:
text/plain; charset="us-ascii"; format=flowed
Reply-To:
[log in to unmask]
Parts/Attachments:
text/plain (14 lines) 
Newest Treatment for Schizophrenia & Related Psychotic Disorders Now 
Available to All Quebecers

 From the PharmaLive.com News Archive - Oct. 26, 2010

Bristol-Myers Squibb Canada is pleased to announce that Quebec has 
recognized the value of Abilify (aripiprazole) for the treatment of 
schizophrenia and related psychotic disorders in adults and has 
agreed to list Abilify as a reimbursed full benefit on the Quebec 
public drug plans as of October 14, 2010.


"People Who experience mood swings, fear, voices and visions"

ATOM RSS1 RSS2